1 ction (PCR) amplification, and quantified by branched DNA assay.

2 naling assays with the high-throughput c-fos branched DNA assay.

3  HGV RNA was measured using a research-based branched DNA assay.

4  reaction and a newly developed quantitative branched DNA assay: 10 patients were positive for serum

5 V and were monitored for plasma viremia by a branched DNA assay 4 weeks later.

6  RNA levels, the Bayer HCV RNA (version 3.0) branched DNA assay and the Abbott HCV analyte-specific r

7 nzyme immunoassay and for HCV RNA by using a branched DNA assay and the HCV COBAS AMPLICOR system.

8  HCV and HGV RNA; HCV RNA was quantitated by branched DNA assay, and HCV genotype was determined.

9 e characteristics of an enhanced-sensitivity branched-DNA assay (bDNA) (Quantiplex HIV-1 version 2.0;

10       We developed and evaluated a multiplex branched DNA assay for the detection and subtyping of av

11 loped small-volume (50 or 250 microl)-format branched-DNA assays for human immunodeficiency virus typ

12                                 The improved branched DNA assay (HCV RNA 2.0) yielded highly reproduc

13 is C virus (HCV)-RNA titers were measured by branched DNA assay (HCV RNA 2.0-Chiron), and there was n

14 titis B virus (HBV) DNA was detectable using branched DNA assay in 46% of HBeAg-negative patients wit

15 erences in maternal HCV load, as measured by branched DNA assay, or mode of delivery.

16                                          The branched DNA assay provides a reliable method for the qu

17 tested retrospectively for HCV RNA levels by branched DNA assay (Quantiplex HCV RNA 2.0 [Chiron Diagn

18 h the Bayer Diagnostics VERSANT HBV DNA 3.0 (branched DNA) assay (r = 0.93).

19 dified set of oligonucleotide probes for the branched DNA assay was developed to enhance the efficien